Insights into the IgG heavy chain engineering patent landscape as applied to IgG4 antibody development
出版年份 2019 全文链接
标题
Insights into the IgG heavy chain engineering patent landscape as applied to IgG4 antibody development
作者
关键词
-
出版物
mAbs
Volume -, Issue -, Pages 1-10
出版商
Informa UK Limited
发表日期
2019-09-26
DOI
10.1080/19420862.2019.1664365
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Extending human IgG half-life using structure-guided design
- (2018) Brian J. Booth et al. mAbs
- Single-dose oral ciprofloxacin prophylaxis as a response to a meningococcal meningitis epidemic in the African meningitis belt: A 3-arm, open-label, cluster-randomized trial
- (2018) Matthew E. Coldiron et al. PLOS MEDICINE
- Investigating interactions between phospholipase B-Like 2 and antibodies during Protein A chromatography
- (2016) Benjamin Tran et al. JOURNAL OF CHROMATOGRAPHY A
- Fusion of an alcohol dehydrogenase with an aminotransferase using a PAS linker to improve coupled enzymatic alcohol-to-amine conversion
- (2016) Alexandra Lerchner et al. PROTEIN ENGINEERING DESIGN & SELECTION
- Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab
- (2015) Giovanna Scapin et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab
- (2015) Giovanna Scapin et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- P-Rex and Vav Rac-GEFs in platelets control leukocyte recruitment to sites of inflammation
- (2014) D. Pan et al. BLOOD
- pH-dependent Binding Engineering Reveals an FcRn Affinity Threshold That Governs IgG Recycling
- (2014) M. Jack Borrok et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody
- (2014) Céline Monnet et al. mAbs
- A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults
- (2013) Gabriel J. Robbie et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Chimeric Anti-CD14 IGG2/4 Hybrid Antibodies for Therapeutic Intervention in Pig and Human Models of Inflammation
- (2013) C. Lau et al. JOURNAL OF IMMUNOLOGY
- Stability of Monoclonal Antibodies at High-Concentration: Head-to-Head Comparison of the IgG1 and IgG4 Subclass
- (2013) Martin S. Neergaard et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Molecular characterization, expression and binding activity of the cytokines TNFSF14 and its receptor LTBR in Oryctolagus cuniculus (rabbit)
- (2013) Xuemei Ji et al. MOLECULAR IMMUNOLOGY
- Engineering an Improved IgG4 Molecule with Reduced Disulfide Bond Heterogeneity and Increased Fab Domain Thermal Stability
- (2012) Shirley J. Peters et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Disulfide bond structures of IgG molecules
- (2012) Hongcheng Liu et al. mAbs
- Influence of improved FcRn binding on the subcutaneous bioavailability of monoclonal antibodies in cynomolgus monkeys
- (2012) Amita Datta-Mannan et al. mAbs
- Hck Tyrosine Kinase Regulates TLR4-Induced TNF and IL-6 Production via AP-1
- (2011) M. J. Smolinska et al. JOURNAL OF IMMUNOLOGY
- Pharmacokinetics of Humanized Monoclonal Anti-Tumor Necrosis Factor- Antibody and Its Neonatal Fc Receptor Variants in Mice and Cynomolgus Monkeys
- (2010) R. Deng et al. DRUG METABOLISM AND DISPOSITION
- IgG2m4, an engineered antibody isotype with reduced Fc function
- (2010) Zhiqiang An et al. mAbs
- Reduced elimination of IgG antibodies by engineering the variable region
- (2010) T. Igawa et al. PROTEIN ENGINEERING DESIGN & SELECTION
- C7 is expressed on endothelial cells as a trap for the assembling terminal complement complex and may exert anti-inflammatory function
- (2009) F. Bossi et al. BLOOD
- Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo
- (2009) Aran F Labrijn et al. NATURE BIOTECHNOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started